Yoko Kataoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoko Kataoka has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Takuya Fujita
Department of Thoracic Surgery Koka Public Hospital Koka Japan
6 shared publicationsJun Hanaoka
Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 5202192, Japan
5 shared publications- Jun Hanaoka
Division of General Thoracic Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan
4 shared publications Tomoyuki Igarashi
Department of Surgery, Shiga University of Medical Science, Otsu, Japan
3 shared publications- Kazuki Hayashi
Division of General Thoracic Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan
2 shared publications - Keigo Okamoto
Department of Cardiothoracic Surgery, Shiga University of Medical Science, Shiga, Japan
2 shared publications
Latest Publications
- Open Access
- 1 March 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (3) , 2232-2245
Dynamic chest radiography in post-lobectomy recovery: a novel approach to evaluating pulmonary function and thoracic structures in patients with primary lung cancer
Background: Lobectomy for lung cancer leads to changes in thoracic structures and reduced pulmonary function, but real-time evaluation of compensatory mechanisms has been challenging. This study employed dynamic chest radiography to examine post-lobectomy changes in the projected lung area and excursion of diaphragm, as evaluated by sequential chest radiography, and determine their correlation with pulmonary function recovery. Methods: This single-center and cross-sectional study was conducted at the Shiga University of Medical Science Hospital and included 65 patients who underwent lobectomy between May 2018 and December 2020. Dynamic chest radiography was performed preoperatively and at 1, 3, 6, and 12 months postoperatively alongside standard pulmonary function tests. We evaluated the postoperative trends in pulmonary function, projected lung area, and excursion of diaphragm. The results were analyzed using the Mann-Whitney U test and Fisher’s exact test. Additionally, correlations between changes in the pulmonary function and dynamic chest radiography (DCR) parameters were assessed using Spearman’s rank correlation coefficients. The utility of DCR in predicting postoperative pulmonary function recovery was further examined using receiver operating characteristic (ROC) curve analysis. Results: Significant correlations were observed between the maximum projected lung area and pulmonary function recovery, particularly in upper lobectomy cases (correlation with vital capacity at 1 month postoperatively: r=0.72, PConclusions: Dynamic chest radiography, which assessed the projected lung area and excursion of diaphragm, emerged as a promising non-invasive tool for monitoring post-lobectomy recovery and guiding rehabilitation efforts. These findings indicate its potential as an early predictor of pulmonary recovery, advocating for its integration into the perioperative care of patients with lung cancer. Future research should expand patient cohorts and refine predictive models using preoperative dynamic chest radiography to enhance post-lobectomy outcomes.
- 1 March 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (3) , 2232-2245
Open AccessDynamic chest radiography in post-lobectomy recovery: a novel approach to evaluating pulmonary function and thoracic structures in patients with primary lung cancer
Background: Lobectomy for lung cancer leads to changes in thoracic structures and reduced pulmonary function, but real-time evaluation of compensatory mechanisms has been challenging. This study employed dynamic chest radiography to examine post-lobectomy changes in the projected lung area and excursion of diaphragm, as evaluated by sequential chest radiography, and determine their correlation with pulmonary function recovery. Methods: This single-center and cross-sectional study was conducted at the Shiga University of Medical Science Hospital and included 65 patients who underwent lobectomy between May 2018 and December 2020. Dynamic chest radiography was performed preoperatively and at 1, 3, 6, and 12 months postoperatively alongside standard pulmonary function tests. We evaluated the postoperative trends in pulmonary function, projected lung area, and excursion of diaphragm. The results were analyzed using the Mann-Whitney U test and Fisher’s exact test. Additionally, correlations between changes in the pulmonary function and dynamic chest radiography (DCR) parameters were assessed using Spearman’s rank correlation coefficients. The utility of DCR in predicting postoperative pulmonary function recovery was further examined using receiver operating characteristic (ROC) curve analysis. Results: Significant correlations were observed between the maximum projected lung area and pulmonary function recovery, particularly in upper lobectomy cases (correlation with vital capacity at 1 month postoperatively: r=0.72, PConclusions: Dynamic chest radiography, which assessed the projected lung area and excursion of diaphragm, emerged as a promising non-invasive tool for monitoring post-lobectomy recovery and guiding rehabilitation efforts. These findings indicate its potential as an early predictor of pulmonary recovery, advocating for its integration into the perioperative care of patients with lung cancer. Future research should expand patient cohorts and refine predictive models using preoperative dynamic chest radiography to enhance post-lobectomy outcomes.
- Open Access
- 17 June 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (6) , e01404
Transudative pleural effusion in pleuritis associated with immunoglobulin G4‐related disease diagnosed by thoracoscopy under local anaesthesia
Immunoglobulin G4 (IgG4)‐related disease is a chronic inflammatory condition often characterized by exudative pleural effusions. However, transudative pleural effusions, like in the presented case of an 80‐year‐old man with multiple comorbidities, are less common but possible. Despite initial treatment with diuretics, the effusion persisted, prompting further investigation. Medical thoracoscopy revealed lymphatic follicle hyperplasia and an abundance of IgG4‐positive plasmacytoid cells, confirming IgG4‐related pleuritis. This case underscores the importance of considering inflammatory etiologies, such as IgG4‐related disease, when faced with unresponsive transudative pleural effusions. Thoracoscopy serves as a valuable diagnostic tool in such scenarios, allowing for precise diagnosis and appropriate management.
- 17 June 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (6) , e01404
Open AccessTransudative pleural effusion in pleuritis associated with immunoglobulin G4‐related disease diagnosed by thoracoscopy under local anaesthesia
Immunoglobulin G4 (IgG4)‐related disease is a chronic inflammatory condition often characterized by exudative pleural effusions. However, transudative pleural effusions, like in the presented case of an 80‐year‐old man with multiple comorbidities, are less common but possible. Despite initial treatment with diuretics, the effusion persisted, prompting further investigation. Medical thoracoscopy revealed lymphatic follicle hyperplasia and an abundance of IgG4‐positive plasmacytoid cells, confirming IgG4‐related pleuritis. This case underscores the importance of considering inflammatory etiologies, such as IgG4‐related disease, when faced with unresponsive transudative pleural effusions. Thoracoscopy serves as a valuable diagnostic tool in such scenarios, allowing for precise diagnosis and appropriate management.
- Open Access
- 5 June 2024
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 50, 102070
Anaplastic thyroid carcinoma transformation in a patient with advanced non-small cell lung cancer treated with PD-1 therapy: A case report
- 5 June 2024
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 50, 102070
Open AccessAnaplastic thyroid carcinoma transformation in a patient with advanced non-small cell lung cancer treated with PD-1 therapy: A case report
- Open Access
- 30 August 2023
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (11) , 3755-3764
Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer
Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (n = 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL, P < 0.001). The combined score of PD-L1-positive cells including tumor cells and tumor-associated macrophages (TAMs) was significantly associated with preoperative plasma sPD-L1 levels. In patients with high levels of preoperative plasma sPD-L1, the probability of 5-year RFS was significantly poor for patients with low PD-L1 expression intensity of tumor cells (tcPD-L1) compared with those with high tcPD-L1 (33.3% vs. 87.5%, respectively, P = 0.016; 95% CI, 0.013–0.964). In former group, PD-L1-positive TAMs were markedly infiltrating compared with those from latter group (246.4 vs. 76.6 counts/mm2, respectively, P = 0.003). In NSCLC, plasma sPD-L1 can reflect the accumulation of PD-L1-posotive TAMs, not just PD-L1-positive tumor cells. In patients with high levels of preoperative plasma sPD-L1, the prognoses after surgery depends on which PD-L1-positive cells, tumor cells or TAMs, are the primary source of the sPD-L1. Thus, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TAMs is of benefit for assessment of postoperative prognosis in operable NSCLC.
- 30 August 2023
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (11) , 3755-3764
Open AccessPrognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer
Programmed cell death-ligand 1 (PD-L1) on tumor cells can be degraded to soluble form (sPD-L1) and enter circulation, however, the clinical significances of sPD-L1 in peripheral blood remains to be elucidated in non-small-cell lung cancer (NSCLC). We monitored plasma sPD-L1 levels during perioperative periods and evaluated PD-L1-positive cells in tumor tissues in patients with operable NSCLC. Then the correlation between preoperative plasma sPD-L1 levels and relapse-free survival (RFS) was analyzed retrospectively. In patients who underwent radical surgery (n = 61), plasma sPD-L1 levels (median; 63.5 pg/mL) significantly increased 1 month after surgery (72.2 pg/mL, P < 0.001). The combined score of PD-L1-positive cells including tumor cells and tumor-associated macrophages (TAMs) was significantly associated with preoperative plasma sPD-L1 levels. In patients with high levels of preoperative plasma sPD-L1, the probability of 5-year RFS was significantly poor for patients with low PD-L1 expression intensity of tumor cells (tcPD-L1) compared with those with high tcPD-L1 (33.3% vs. 87.5%, respectively, P = 0.016; 95% CI, 0.013–0.964). In former group, PD-L1-positive TAMs were markedly infiltrating compared with those from latter group (246.4 vs. 76.6 counts/mm2, respectively, P = 0.003). In NSCLC, plasma sPD-L1 can reflect the accumulation of PD-L1-posotive TAMs, not just PD-L1-positive tumor cells. In patients with high levels of preoperative plasma sPD-L1, the prognoses after surgery depends on which PD-L1-positive cells, tumor cells or TAMs, are the primary source of the sPD-L1. Thus, measuring both plasma sPD-L1 levels and PD-L1 expression status of tumor cells and TAMs is of benefit for assessment of postoperative prognosis in operable NSCLC.
- Open Access
- 31 July 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (9) , e01196
A case of primary lung cancer requiring differentiation from metastatic cervical cancer
P16 has been used as a surrogate marker for human papillomavirus (HPV)‐related tumours. However, it remains unclear whether p16 is also a potential marker for pulmonary tumours. Herein, we report the case of an 80‐year‐old woman with a history of papillary squamous cell carcinoma of the uterine cervix, presenting with a left pulmonary tumour. A bronchoscopic biopsy revealed squamous cell carcinoma with a papillary pattern, which did not rule out pulmonary metastasis from the cervix. Immunohistochemical staining revealed that the cervical tumour was positive for p16, whereas the pulmonary tumour was negative and was effectively diagnosed as primary pulmonary carcinoma.
- 31 July 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (9) , e01196
Open AccessA case of primary lung cancer requiring differentiation from metastatic cervical cancer
P16 has been used as a surrogate marker for human papillomavirus (HPV)‐related tumours. However, it remains unclear whether p16 is also a potential marker for pulmonary tumours. Herein, we report the case of an 80‐year‐old woman with a history of papillary squamous cell carcinoma of the uterine cervix, presenting with a left pulmonary tumour. A bronchoscopic biopsy revealed squamous cell carcinoma with a papillary pattern, which did not rule out pulmonary metastasis from the cervix. Immunohistochemical staining revealed that the cervical tumour was positive for p16, whereas the pulmonary tumour was negative and was effectively diagnosed as primary pulmonary carcinoma.
- Open Access
- 28 December 2022
- Published by Wiley in Cancer Science
- Vol. 114 (3) , 750-763
Depletion of tumor‐associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin
In lung cancer, tumor‐associated macrophages (TAMs), especially M2‐like TAMs, represent the main tumor progression components in the tumor microenvironment (TME). Therefore, M2‐like TAMs may serve as a therapeutic target. The purpose of this study was to investigate the effect of M2‐like TAM depletion in the TME on tumor growth and chemotherapy response in lung cancer. The levels of secreted monocyte chemoattractant protein (MCP‐1) and prostaglandin E2 (PGE2) in the supernatants of lung cancer cell lines A549 and LLC were evaluated via ELISA. Cell migration assays were performed to assess the recruitment ability of macrophage cell lines THP‐1 and J774‐1 cells. Differentiation of macrophages was assessed via flow cytometry. Immunohistochemical staining was performed to visualize M2‐like TAMs in transplanted lung cancer in mouse. We used the COX‐2 inhibitor nimesulide to inhibit the secretion of MCP‐1 and PGE2, which promotes macrophage migration and M2‐like differentiation. Nimesulide treatment decreased the secretion of MCP‐1 and PGE2 from lung cancer cells. Nimesulide treatment suppressed the migration of macrophages by blocking MCP‐1. Lung cancer supernatant induced the differentiation of macrophages toward the M2‐like phenotype, and nimesulide treatment inhibited M2‐like differentiation by blocking MCP‐1 and PGE2. In the lung cancer mouse model, treatment with nimesulide depleted M2‐like TAMs in the TME and enhanced the tumor inhibitory effect of cisplatin. Our results indicated that blocking the secretion of MCP‐1 and PGE2 from tumor cells depleted M2‐like TAMs in the TME and the combination therapy with cisplatin considerably suppressed tumor growth in the LLC mouse model.
- 28 December 2022
- Published by Wiley in Cancer Science
- Vol. 114 (3) , 750-763
Open AccessDepletion of tumor‐associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin
In lung cancer, tumor‐associated macrophages (TAMs), especially M2‐like TAMs, represent the main tumor progression components in the tumor microenvironment (TME). Therefore, M2‐like TAMs may serve as a therapeutic target. The purpose of this study was to investigate the effect of M2‐like TAM depletion in the TME on tumor growth and chemotherapy response in lung cancer. The levels of secreted monocyte chemoattractant protein (MCP‐1) and prostaglandin E2 (PGE2) in the supernatants of lung cancer cell lines A549 and LLC were evaluated via ELISA. Cell migration assays were performed to assess the recruitment ability of macrophage cell lines THP‐1 and J774‐1 cells. Differentiation of macrophages was assessed via flow cytometry. Immunohistochemical staining was performed to visualize M2‐like TAMs in transplanted lung cancer in mouse. We used the COX‐2 inhibitor nimesulide to inhibit the secretion of MCP‐1 and PGE2, which promotes macrophage migration and M2‐like differentiation. Nimesulide treatment decreased the secretion of MCP‐1 and PGE2 from lung cancer cells. Nimesulide treatment suppressed the migration of macrophages by blocking MCP‐1. Lung cancer supernatant induced the differentiation of macrophages toward the M2‐like phenotype, and nimesulide treatment inhibited M2‐like differentiation by blocking MCP‐1 and PGE2. In the lung cancer mouse model, treatment with nimesulide depleted M2‐like TAMs in the TME and enhanced the tumor inhibitory effect of cisplatin. Our results indicated that blocking the secretion of MCP‐1 and PGE2 from tumor cells depleted M2‐like TAMs in the TME and the combination therapy with cisplatin considerably suppressed tumor growth in the LLC mouse model.
- Open Access
- 8 November 2022
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 40, 101779
Pulmonary spindle cell carcinoma presenting with hemothorax
- 8 November 2022
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 40, 101779
Open AccessPulmonary spindle cell carcinoma presenting with hemothorax
- 1 July 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (1) , e47-e50
Coincidence of Thyroid Transcription Factor-1-Positive Thymoma and Pulmonary Adenocarcinoma
- 1 July 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (1) , e47-e50
Coincidence of Thyroid Transcription Factor-1-Positive Thymoma and Pulmonary Adenocarcinoma
- 22 March 2019
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 67 (8) , 704-711
Predictive importance of galectin-3 for recurrence of non-small cell lung cancer
The predictive importance of galectin-3 in non-small cell lung cancer (NSCLC) has not been elucidated. We examined whether galectin-3 could serve as a predictor for tumor recurrence in NSCLC.
- 22 March 2019
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 67 (8) , 704-711
Predictive importance of galectin-3 for recurrence of non-small cell lung cancer
The predictive importance of galectin-3 in non-small cell lung cancer (NSCLC) has not been elucidated. We examined whether galectin-3 could serve as a predictor for tumor recurrence in NSCLC.
- Open Access
- 1 January 2015
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 29 (6) , 727-731
Lung squamous cell carcinoma combined with partial anomalous pulmonary venous connect in the same lobe: A case report
- 1 January 2015
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 29 (6) , 727-731
Open AccessLung squamous cell carcinoma combined with partial anomalous pulmonary venous connect in the same lobe: A case report